Patent ID: 11890350
Assignee: DEFENCE THERAPEUTICS INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A

Claim 7:
8. The pharmaceutical composition of claim 1, wherein the nuclear localization signal is a/an: SV40 NLS (SEQ ID NO: 1 or 2), GWG-SV40 NLS (SEQ ID NO: 3), hnRNPA1 M9 NLS (SEQ ID NO: 4), hnRNP D NLS (SEQ ID NO: 5), hnRNP M NLS (SEQ ID NO: 6), PQBP-1 NLS (SEQ ID NO: 7), NLS2-RG Domain RPS17 (SEQ ID NO: 8), NL S1 RPS17 SEQ ID NO: 9), NLS2 RPS17 (SEQ ID NO: 10), NLS3 RPS17 (SEQ ID NO: 11), cMyc NLS (SEQ ID NO: 12), HuR NLS (SEQ ID NO: 13), Tus NLS (SEQ ID NO: 14), or Nucleoplasmin NLS (SEQ ID NO: 15).